https://www.biopharmawatch.com/news/INO/inovio-fda-accelerated-approval-voceryq-rrp BiopharmaWatch en 2026-10-30T22:01:00.000Z INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP) https://www.biopharmawatch.com/news/ACET/adicet-bio-inducement-grant-nasdaq-listing-rule BiopharmaWatch en 2026-10-30T21:38:00.000Z Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inducement-grant-new-employee BiopharmaWatch en 2026-10-30T21:15:00.000Z Actinium Pharmaceuticals Announces Inducement Grant to New Employee https://www.biopharmawatch.com/news/ANVS/annovis-bio-nyse-listing-notice BiopharmaWatch en 2026-10-30T21:00:00.000Z Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE https://www.biopharmawatch.com/news/ACH/accendra-health-receives-continued-listing-standard-notice-nyse-regarding-market BiopharmaWatch en 2026-10-30T20:45:00.000Z Accendra Health Receives Continued Listing Standard Notice from NYSE Regarding Market Capitalization and Stockholders’ Equity; Intends to Submit Business Plan and Return to Compliance with NYSE Listing Standard https://www.biopharmawatch.com/news/MTD/mettlertoledo-investor-conferences-november-2023 BiopharmaWatch en 2026-10-30T20:30:00.000Z Mettler-Toledo International Inc. to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-inducement-grants-october-2026 BiopharmaWatch en 2026-10-30T20:30:00.000Z PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ARAY/accuray-inducement-award-nasdaq-rules BiopharmaWatch en 2026-10-30T20:10:00.000Z Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules https://www.biopharmawatch.com/news/UHS/universal-health-services-presentation-ubs-conference BiopharmaWatch en 2026-10-30T20:09:47.000Z Universal Health Services, Inc. to Present at The UBS Global Healthcare Conference https://www.biopharmawatch.com/news/GILD/gilead-sciences-investor-conferences-november-december-2026 BiopharmaWatch en 2026-10-30T20:05:00.000Z Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-upcoming-conference-presentations BiopharmaWatch en 2026-10-30T20:05:00.000Z Tandem Diabetes Care Announces Upcoming Conference Presentations https://www.biopharmawatch.com/news/RVTY/revvity-board-declares-quarterly-dividend-20261030 BiopharmaWatch en 2026-10-30T20:05:00.000Z Revvity Board Declares Quarterly Dividend https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-nasdaq-listing-rule-5635-c-4-20261030 BiopharmaWatch en 2026-10-30T20:05:00.000Z TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/DYAI/dyadic-report-q3-2026-financial-results-conference-call BiopharmaWatch en 2026-10-30T20:05:00.000Z Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026 https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-inducement-grants-october-2026 BiopharmaWatch en 2026-10-30T20:01:00.000Z Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/PHG/philips-launches-hypervue-integrated-system-cathlab BiopharmaWatch en 2026-10-30T20:00:00.000Z Philips launches HyperVue Integrated System in the U.S., bringing advanced coronary imaging and physiology into the cathlab https://www.biopharmawatch.com/news/SRXH/srx-global-balance-sheet-share-buyback-update BiopharmaWatch en 2026-10-30T19:16:00.000Z SRX Global Provides Update on Balance Sheet and Share Buyback https://www.biopharmawatch.com/news/RVMD/revolution-medicines-excellence-client-partnership-award BiopharmaWatch en 2026-10-30T16:00:00.000Z Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award" https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-announces-1-4-reverse-stock-split BiopharmaWatch en 2026-10-30T14:30:00.000Z Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split